Stone Mars, Lanteri Marion C, Bakkour Sonia, Deng Xutao, Galel Susan A, Linnen Jeffrey M, Muñoz-Jordán Jorge L, Lanciotti Robert S, Rios Maria, Gallian Pierre, Musso Didier, Levi José E, Sabino Ester C, Coffey Lark L, Busch Michael P
Blood Systems Research Institute, University of California-San Francisco, San Francisco, California.
Department of Laboratory Medicine, University of California-San Francisco, San Francisco, California.
Transfusion. 2017 Mar;57(3pt2):734-747. doi: 10.1111/trf.14031. Epub 2017 Feb 14.
Zika virus (ZIKV) has spread rapidly in the Pacific and throughout the Americas and is associated with severe congenital and adult neurologic outcomes. Nucleic acid amplification technology (NAT) assays were developed for diagnostic applications and for blood donor screening on high-throughput NAT systems. We distributed blinded panels to compare the analytical performance of blood screening relative to diagnostic NAT assays.
A 25-member, coded panel (11 half-log dilutions of a 2013 French Polynesia ZIKV isolate and 2015 Brazilian donor plasma implicated in transfusion transmission, and 3 negative controls) was sent to 11 laboratories that performed 17 assays with 2 to 12 replicates per panel member. Results were analyzed for the percentage reactivity at each dilution and by probit analysis to estimate the 50% and 95% limits of detection (LOD and LOD , respectively).
Donor-screening NAT assays that process approximately 500 µL of plasma into amplification reactions were comparable in sensitivity (LOD and LOD , 2.5 and 15-18 copies/mL) and were approximately 10-fold to 100-fold more sensitive than research laboratory-developed and diagnostic reverse transcriptase-polymerase chain reaction tests that process from 10 to 30 µL of plasma per amplification. Increasing sample input volume assayed with the Centers for Disease Control and Prevention reverse transcriptase-polymerase chain reaction assays increased the LODs by 10-fold to 30-fold.
Blood donor-screening ZIKV NAT assays demonstrate similar excellent sensitivities to assays currently used for screening for transfusion-transmitted viruses and are substantially more sensitive than most other laboratory-developed and diagnostic ZIKV reverse transcriptase-polymerase chain reaction assays. Enhancing sensitivities of laboratory-developed and diagnostic assays may be achievable by increasing sample input.
寨卡病毒(ZIKV)已在太平洋地区和整个美洲迅速传播,并与严重的先天性和成人神经系统疾病相关。核酸扩增技术(NAT)检测方法已被开发用于诊断应用以及在高通量NAT系统上进行献血者筛查。我们分发了盲法样本板,以比较血液筛查相对于诊断性NAT检测方法的分析性能。
一个包含25个样本的编码样本板(2013年法属波利尼西亚寨卡病毒分离株的11个半对数稀释度、2015年涉及输血传播的巴西献血者血浆以及3个阴性对照)被发送至11个实验室,这些实验室对每个样本进行了17次检测,每个样本重复检测2至12次。分析每个稀释度下的反应性百分比,并通过概率分析来估计50%和95%的检测限(分别为LOD和LOD )。
将约500µL血浆用于扩增反应的献血者筛查NAT检测方法在灵敏度方面相当(LOD和LOD分别为2.5和15 - 18拷贝/ mL),并且比每个扩增反应处理10至30µL血浆的研究实验室开发的和诊断性逆转录聚合酶链反应检测方法灵敏约10倍至100倍。使用疾病控制与预防中心逆转录聚合酶链反应检测方法检测的样本输入量增加,使检测限提高了10倍至30倍。
献血者筛查寨卡病毒NAT检测方法与目前用于筛查输血传播病毒的检测方法具有相似的出色灵敏度,并且比大多数其他实验室开发的和诊断性寨卡病毒逆转录聚合酶链反应检测方法灵敏得多。通过增加样本输入量,可能提高实验室开发的和诊断性检测方法的灵敏度。